Antimony is trading on its own story as the critical minerals complex splits in two. United States Antimony (NYSEAMERICAN:UAMY) shares are up 11% to $3.18, breaking clearly from the rare earth names around it.…
Apple's first foldable iPhone sold out in minutes and sent investors scrambling to find the supplier that could pull off what one obscure chipmaker did after the original iPhone launched in 2007.
Both payroll giants just handed investors a 10% dividend raise, yet one pays nearly twice the yield of the other while trading at a steeper discount. The right pick depends on a tension between…
A Pulitzer Prize-winning historian of financial crashes sees a familiar pattern forming in today's AI boom, and he says the same mechanism that buried railroads in 1873 and dot-coms in 2000 is already flashing…
He inherited a $900,000 Manhattan apartment free and clear, but a co-op board still holds the power to decide whether he can keep it, and the answer depends on paperwork that has nothing to…
She spent 12 years sleeping under the same roof, managing the pill organizers and the 2 a.m. falls, and now a six-figure state claim stands between her and the house she never left. Whether…
One crypto tripled on a landmark bank network deal while the other quietly bleeds alongside the broader altcoin market. Before you chase the winner or bet on a rebound, there are red flags in…
Palantir just posted its fastest commercial growth ever, but the valuation math raises a question that every investor needs to answer before buying in at current prices.
Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline numbers suggest.